Labtech International, a distributor of life science instrumentation in the UK and France, has agreed to provide a global sales and marketing support service for the G-Storm PCR machines that target the international life science research market.
The agreement allows Agilegene Technologies, the UK manufacturer of the G-Storm PCR machines, to focus solely on engineering and software development of future products.
With 19 years of sales and marketing experience in the life science instrumentation sector, Labtech International, based in Ringmer, Sussex, is suitably equipped to offer G-Storm's global distributors and customers a high-quality sales support service.
The G-Storm thermal cyclers in a striking new black livery are purpose-built to meet the demands of molecular biology. The G-Storm touch-screen user interface is easy to use and makes programming, file management and cycler control a simple process.
Labtech to support G-Storm PCR machines
G-Storm machines are given a new black livery
You may also like
Manufacturing
Titan Enterprises develops PFAS-free material options for turbine flowmeters
Read moreTitan Enterprises is evaluating high-performance, PFAS-free polymers for its turbine flowmeter range, aiming to maintain accuracy, durability and reliability while preparing for evolving international regulations
Trending Articles
You may also like
Manufacturing
Titan Enterprises develops PFAS-free material options for turbine flowmeters
Titan Enterprises is evaluating high-performance, PFAS-free polymers for its turbine flowmeter range, aiming to maintain accuracy, durability and reliability while preparing for evolving international regulations
Manufacturing
What makes a GMP quality system effective in day-to-day pharmaceutical manufacturing?
Your quality system may have a procedure for almost everything: reporting a deviation, reviewing a batch record, changing equipment settings and training the people who operate it. But having a procedure and getting a useful answer from it are two different things
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
Scaling complexity without losing control: how manufacturing processes are adapting to the next generation of medicines (part V)
As therapies grow more complex, manufacturers must build commercial-scale thinking into early development, focus on meaningful monitoring and favour simplicity to keep production predictable